Two New Colorectal-Cancer Drugs coming

As reported in the Wall Street Journal, ImClone's Erbitux is expected to be approved by Friday and Genentech's Avastin is scheduled to the end of March. Options on DNA and IMCL may deserve due diligence.

DNA $97.95 on 2/12/2004

IMCL $43.96 on 2/12/2004